ATE352563T1 - Transplantatabstossung und damit verbundene zustände - Google Patents

Transplantatabstossung und damit verbundene zustände

Info

Publication number
ATE352563T1
ATE352563T1 AT00979785T AT00979785T ATE352563T1 AT E352563 T1 ATE352563 T1 AT E352563T1 AT 00979785 T AT00979785 T AT 00979785T AT 00979785 T AT00979785 T AT 00979785T AT E352563 T1 ATE352563 T1 AT E352563T1
Authority
AT
Austria
Prior art keywords
transplant rejection
related conditions
rejection
transducin
traf
Prior art date
Application number
AT00979785T
Other languages
English (en)
Inventor
Lydia Rose Marlene
John Dunn Michael
Linke Adam
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of ATE352563T1 publication Critical patent/ATE352563T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT00979785T 1999-11-29 2000-11-29 Transplantatabstossung und damit verbundene zustände ATE352563T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9928136.2A GB9928136D0 (en) 1999-11-29 1999-11-29 Organ rejection and associated conditions

Publications (1)

Publication Number Publication Date
ATE352563T1 true ATE352563T1 (de) 2007-02-15

Family

ID=10865318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00979785T ATE352563T1 (de) 1999-11-29 2000-11-29 Transplantatabstossung und damit verbundene zustände

Country Status (10)

Country Link
US (1) US7132245B2 (de)
EP (1) EP1242450B1 (de)
AT (1) ATE352563T1 (de)
AU (1) AU780041B2 (de)
CA (1) CA2390778C (de)
DE (1) DE60033183T2 (de)
DK (1) DK1242450T3 (de)
ES (1) ES2281364T3 (de)
GB (1) GB9928136D0 (de)
WO (1) WO2001040302A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018614D0 (en) 2000-07-28 2000-09-13 Rose Marlene L Organ transplant rejection and associated conditions
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20070243561A1 (en) * 2006-02-16 2007-10-18 Ben Geeraerts Prognostic markers in chronic lymphocytic leukemia
US8735178B2 (en) * 2006-03-27 2014-05-27 University Of Kentucky Research Foundation Withanolides, probes and binding targets and methods of use thereof
US20090176664A1 (en) * 2007-06-01 2009-07-09 Keting Chu High density peptide arrays containing kinase or phosphatase substrates
JP2017502672A (ja) * 2013-12-30 2017-01-26 メディシナル バイオコンバージェンス リサーチ センター 抗ｋｒｓモノクロナル抗体及びこれの用途
US20170082619A1 (en) 2015-09-23 2017-03-23 One Lambda, Inc. Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens
BR112019020166A2 (pt) 2017-03-27 2020-06-30 Medicinal Bioconvergence Research Center anticorpo que se liga especificamente a região n-terminal de lisil-trna sintetase exposta na membrana celular
WO2018182284A1 (ko) * 2017-03-27 2018-10-04 재단법인 의약바이오컨버젼스연구단 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
CA3084461C (en) 2017-09-15 2025-06-17 Zymedi Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY THAT BINDS SPECIFICALLY TO THE N-TERMINAL END OF LYSYL TRANSFER RIBONUCLE ACID (NTRNA) SYNTHETASE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A DISEASE RELATED TO IMMUNE CELL MIGRATION
WO2020060156A1 (ko) * 2018-09-17 2020-03-26 재단법인 의약바이오컨버젼스연구단 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2268935B (en) 1992-06-24 1996-10-23 Nat Heart & Lung Inst Diagnosis of rejection of transplanted organs
GB0018614D0 (en) 2000-07-28 2000-09-13 Rose Marlene L Organ transplant rejection and associated conditions

Also Published As

Publication number Publication date
WO2001040302A2 (en) 2001-06-07
EP1242450A2 (de) 2002-09-25
GB9928136D0 (en) 2000-01-26
DE60033183T2 (de) 2007-11-08
AU1717301A (en) 2001-06-12
ES2281364T3 (es) 2007-10-01
WO2001040302A3 (en) 2002-03-21
US7132245B2 (en) 2006-11-07
CA2390778A1 (en) 2001-06-07
DK1242450T3 (da) 2007-05-29
DE60033183D1 (de) 2007-03-15
AU780041B2 (en) 2005-02-24
CA2390778C (en) 2010-06-15
EP1242450B1 (de) 2007-01-24
US20050277157A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
ATE352563T1 (de) Transplantatabstossung und damit verbundene zustände
DK0784683T3 (da) TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DK1356052T3 (da) Produktion af hele antistoffer i prokaryotiske celler
EP2112167A3 (de) Humanisierte ANTI-ERBB2-Antikörper und Behandlung mit ANTI-ERBB2-Antikörpern
DE50106127D1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60140252D1 (de) Agonistische monoklonale antikörper gegen trkc
EP1650220A3 (de) Anti-VEFG Antikörper
EP1137658A4 (de) VERFAHREN ZUR MODULATION VON TUMOR NECROSIS FAKTOR -g(a)-INDUZIERTER EXPRESSION VON ZELLADHÄSIONSMOLEKÜLEN
WO2004041865A3 (en) Stabilized single domain antibodies
EE05558B1 (et) Antikeha v?i selle antigeeni siduva fragmendi v?i lahustuva polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks
ATE336506T1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
ATE384263T1 (de) Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen
WO2004069860A3 (en) Isg15-conjugated proteins
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
WO2004083241A3 (en) Btc-interacting proteins and use thereof
WO2005094159A3 (en) Methods of identifying neoplasm-specific antibodies and uses thereof
WO2023225197A3 (en) Klrb1 binding agents and methods of use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242450

Country of ref document: EP